{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-028854","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.232948+00:00","generated_at":"2026-05-15T00:37:03.726676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated","bullets":["Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).","GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.","Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.","Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.","Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-028854","json":"https://secwatch.observer/filing/0001628280-26-028854.json","markdown":"https://secwatch.observer/filing/0001628280-26-028854.md","text":"https://secwatch.observer/filing/0001628280-26-028854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/0001628280-26-028854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:37:03.726676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29fce173d404c1238f0a94507e7b92886be3e785","claim":"Pacira BioSciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $177.4 million, net income $2.9 million, or $0.07 per share (basic and diluted).","evidence_excerpt":"reference in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2026 Financial Results -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/0001628280-26-028854-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$177.4 million"},{"label":"Net income","value":"$2.9 million, or $0.07 per share (basic and diluted)"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}